Operator error: A critical determinant of false amikacin and tobramycin concentrations using fluorescence polarization immunoassay kits and TDX analyzer

被引:12
作者
Banerjee, SK [1 ]
Wells, A [1 ]
Dasgupta, A [1 ]
机构
[1] Univ Texas, Sch Med, Dept Pathol & Lab Med, Houston, TX 77030 USA
关键词
amikacin; tobramycin; fluorescence polarization; operator error;
D O I
10.1097/00007691-199910000-00009
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Amikacin and tobramycin are aminoglycosides used to treat seven Gram-negative infections. Therapeutic monitoring of both drugs is essential to avoid drug toxicity. Fluorescence polarization immunoassay kits for both amikacin and tobramycin are available from Abbott Laboratories, and assays can be run using the TDx analyzer. The test code for amikacin is 3, whereas the test code for tobramycin is 2. Here the authors report that when the operator mistakenly programmed test code 3 (amikacin code) while using the tobramycin kit, the tobramycin values were falsely elevated. The instrument software does not have any mechanism to detect this error. Similarly, when the amikacin kit was used and the operator mistakenly programmed test code 2 (tobramycin code), the amikacin values were falsely lowered. For trample, in a serum sample taken from a patient the true amikacin concentration was 20.9 mu g/mL. When the amikacin kit was used correctly but test code 2 was programmed, the observed concentration was falsely lowered to 6.1 mu g/mL. Similarly, in another specimen the: true tobramycin concentration was 3.1 mu g/mL. However, when the tobramycin kit was used correctly but test code 3 was used, the observed concentration was falsely elevated to 14.3 mu g/mL. The authors also observed a similar effect with controls and spiked specimens containing either amikacin or tobramycin. They conclude that correct programming of the test code is vital to obtaining useful results in amikacin and tobramycin analysis using the TDx analyzer.
引用
收藏
页码:540 / 543
页数:4
相关论文
共 8 条
[1]  
ACAR JF, 1976, J INFECT DIS, V134, P280
[2]   TOBRAMYCIN - REVIEW OF ITS ANTIBACTERIAL AND PHARMACOKINETIC PROPERTIES AND THERAPEUTIC USE [J].
BROGDEN, RN ;
PINDER, RM ;
SAWYER, PR ;
SPEIGHT, TM ;
AVERY, GS .
DRUGS, 1976, 12 (03) :166-200
[3]   Adaptation of total phenytoin reagent pack for measuring free phenytoin levels with the Abbott AxSYM immunoassay analyzer [J].
Jarzabek, JI ;
Kampa, IS .
THERAPEUTIC DRUG MONITORING, 1999, 21 (01) :134-136
[4]   AMINOGLYCOSIDE NEPHROTOXICITY [J].
KALOYANIDES, GJ ;
PASTORIZAMUNOZ, E .
KIDNEY INTERNATIONAL, 1980, 18 (05) :571-582
[5]  
Lerner S A, 1980, Am J Otolaryngol, V1, P169, DOI 10.1016/S0196-0709(80)80012-3
[6]  
LEW M, 1979, HOSP PHARM, V14, P465
[7]  
PIERCE KE, 1976, J INFECT DIS, V134, P249
[8]   AMIKACIN THERAPY FOR SEVERE GRAM-NEGATIVE SEPSIS - EMPHASIS ON INFECTIONS WITH GENTAMICIN-RESISTANT ORGANISMS [J].
TALLY, FP ;
LOUIE, TJ ;
WEINSTEIN, WM ;
BARTLETT, JG ;
GORBACH, SL .
ANNALS OF INTERNAL MEDICINE, 1975, 83 (04) :484-488